{"ATC Code":"N05AH04","Abbreviation":"","Aliases":["Seroquel","quetiapina","Quetiapine fumarate","Norsic","Co-Quetiapine","quetiapinum","BGL0JSY5SI","Quetiapine extended release","Quetiapine (INN)","2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol"],"Biological Half-Life":"The average terminal half-life of quetiapine is about 6-7 hours.","Boiling Point":"556.5±60.0","CAS":"111974-69-7","ChEBI":"CHEBI:8707","ChEMBL":"CHEMBL716","Chirality":"achiral","Color/Form":"Solid","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Lower":25,"Upper":58},"Heavy":{"Lower":150,"Upper":200},"Light":{"Lower":19.250000000000004,"Upper":25},"Strong":{"Lower":58,"Upper":150},"Threshold":{"Lower":1,"Upper":19.250000000000004}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents","Drug Indication":"Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.  Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.","Drug Warnings":"/BOXED WARNING/ WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA- RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS:  Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Quetiapine is not approved for the treatment of patients with dementia-related psychosis.    Suicidal Thoughts and Behaviors:  Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.  Quetiapine is not approved for use in pediatric patients under ten years of age.","DrugClasses":["antipsychotic","antidepressant","depressant"],"European Community (EC) Number":"601-143-7","FDA Pharmacological Classification":"BGL0JSY5SI","Flash Point":"9.7 °C (49.5 °F) - closed cup","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents","IUPACName":"2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol","InChI":"InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2","InChIKey":"URKOMYMAXPYINW-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)","Melting Point":"174-176","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003eS","MolecularWeight":"383.5 g/mol","Pharmacodynamics":"Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.  **A note on suicidality in young patients and administration in the elderly**  Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.","Physical Description":"Solid","PubChemId":5002,"Record Description":["Quetiapine is a dibenzothiazepine, a N-alkylpiperazine and a N-arylpiperazine. It has a role as a serotonergic antagonist, a dopaminergic antagonist, a histamine antagonist, an adrenergic antagonist and a second generation antipsychotic.","Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].","Quetiapine is an Atypical Antipsychotic.","Quetiapine is an atypical antipsychotic used in the treatment of schizophrenia and bipolar disorder. Use of quetiapine has been associated with serum aminotransferase elevations and in rare instances with clinically apparent acute liver injury.","Quetiapine Fumarate is the fumarate salt form of quetiapine, a dibenzothiazepine derivative with antipsychotic property. Quetiapine fumarate antagonizes serotonin activity mediated by 5-HT 1A and 5-HT2 receptors. With a lower affinity, this agent also reversibly binds to dopamine D1 and D2 receptors in the mesolimbic and mesocortical areas of the brain leading to decreased psychotic effects, such as hallucinations and delusions. In addition, quetiapine fumarate also binds to other alpha-1, alpha-2 adrenergic and histamine H1 receptors.","Quetiapine is a dibenzothiazepine derivative with antipsychotic property. Quetiapine fumarate antagonizes serotonin activity mediated by 5-HT 1A and 5-HT2 receptors. With a lower affinity, this agent also reversibly binds to dopamine D1 and D2 receptors in the mesolimbic and mesocortical areas of the brain leading to decreased psychotic effects, such as hallucinations and delusions. In addition, quetiapine also binds to other alpha-1, alpha-2 adrenergic and histamine H1 receptors.","QUETIAPINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 8 approved and 39 investigational indications. This drug has a black box warning from the FDA.","The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as atypical antipsychotics, which have become increasingly popular alternatives to typical antipsychotics such as haloperidol. Quetiapine HAS approvals for the treatment of schizophrenia and acute mania in bipolar disorder. It is also used off-label to treat other disorders, such as post-traumatic stress disorder, alcoholism, obsessive compulsive disorder, anxiety disorders, hallucinations in Parkinson's disease patients using ropinirole, and as a sedative for those with sleep disorders. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited.","A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.","See also: Quetiapine Fumarate (has salt form).","Quetiapine is a dibenzothiazepine, a N-alkylpiperazine and a N-arylpiperazine. It has a role as a serotonergic antagonist, a dopaminergic antagonist, a histamine antagonist, an adrenergic antagonist and a second generation antipsychotic.","LiverTox|CNS|Antipsychotic|Atypical"],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Quetiapine"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q408535"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB01224"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/5002"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.4827.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL716"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8707"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=111974-69-7"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0005021"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C07397"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/BGL0JSY5SI"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9023546"}],"SMILES":"C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42","Solubility":"49.4 [ug/mL] (The mean of the results at pH 7.4)","Stability/Shelf Life":"Stable under recommended storage conditions.","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="161.414mm" version="1.2" viewBox="0 0 87.86 161.414" width="87.86mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="162.0" stroke="none" width="88.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="7.921" x2="14.519" y1="66.798" y2="53.051"/>
                  
            <line class="bond" id="mol1bnd2" x1="14.519" x2="26.386" y1="53.051" y2="52.138"/>
                  
            <line class="bond" id="mol1bnd3" x1="32.189" x2="38.328" y1="55.487" y2="64.459"/>
                  
            <line class="bond" id="mol1bnd4" x1="38.328" x2="31.73" y1="64.459" y2="78.206"/>
                  
            <line class="bond" id="mol1bnd5" x1="31.73" x2="19.864" y1="78.206" y2="79.119"/>
                  
            <line class="bond" id="mol1bnd6" x1="7.921" x2="14.06" y1="66.798" y2="75.77"/>
                  
            <line class="bond" id="mol1bnd7" x1="14.747" x2="9.939" y1="83.088" y2="93.119"/>
                  
            <line class="bond" id="mol1bnd8" x1="9.939" x2="18.547" y1="93.119" y2="105.695"/>
                  
            <line class="bond" id="mol1bnd9" x1="18.547" x2="13.667" y1="105.695" y2="115.876"/>
                  
            <line class="bond" id="mol1bnd10" x1="14.181" x2="20.567" y1="122.683" y2="132.014"/>
                  
            <line class="bond" id="mol1bnd11" x1="20.567" x2="13.98" y1="132.014" y2="145.757"/>
                  
            <line class="bond" id="mol1bnd12" x1="13.98" x2="20.362" y1="145.757" y2="155.081"/>
                  
            <line class="bond" id="mol1bnd13" x1="31.502" x2="36.31" y1="48.169" y2="38.139"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="36.31" x2="48.209" y1="38.139" y2="38.139"/>
                        
                <line x1="37.479" x2="48.209" y1="35.7" y2="35.7"/>
                      
                <line class="hi" stroke="#3050F8" x1="48.209" x2="42.2595" y1="38.139" y2="38.139"/>
                <line class="hi" stroke="#3050F8" x1="48.209" x2="42.844" y1="35.7" y2="35.7"/>
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="54.368" x2="61.1" y1="34.632" y2="26.251"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="61.1" x2="75.629" y1="26.251" y2="30.722"/>
                        
                <line x1="63.157" x2="75.002" y1="24.333" y2="27.978"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="75.629" x2="86.805" y1="30.722" y2="20.359"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="86.805" x2="83.351" y1="20.359" y2="5.525"/>
                        
                <line x1="84.109" x2="81.294" y1="19.533" y2="7.443"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="83.351" x2="68.822" y1="5.525" y2="1.055"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="68.822" x2="57.646" y1="1.055" y2="11.418"/>
                        
                <line x1="69.449" x2="60.342" y1="3.799" y2="12.243"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="61.1" x2="57.646" y1="26.251" y2="11.418"/>
                  
            <line class="bond" id="mol1bnd22" x1="57.646" x2="46.736" y1="11.418" y2="6.165"/>
                  
            <line class="bond" id="mol1bnd23" x1="41.14" x2="30.214" y1="6.157" y2="11.418"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="30.214" x2="19.038" y1="11.418" y2="1.055"/>
                        
                <line x1="27.518" x2="18.411" y1="12.243" y2="3.799"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="19.038" x2="4.509" y1="1.055" y2="5.525"/>
                  
            <g class="bond" id="mol1bnd26">
                        
                <line x1="4.509" x2="1.055" y1="5.525" y2="20.359"/>
                        
                <line x1="6.566" x2="3.751" y1="7.443" y2="19.533"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd27" x1="1.055" x2="12.231" y1="20.359" y2="30.722"/>
                  
            <g class="bond" id="mol1bnd28">
                        
                <line x1="12.231" x2="26.759" y1="30.722" y2="26.251"/>
                        
                <line x1="12.858" x2="24.703" y1="27.978" y2="24.333"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd29" x1="30.214" x2="26.759" y1="11.418" y2="26.251"/>
                  
            <line class="bond" id="mol1bnd30" x1="36.31" x2="26.759" y1="38.139" y2="26.251"/>
                  
            <path class="atom" d="M31.663 54.331h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .358 .024 .733v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.328q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M18.468 81.825h-.721l-2.619 -4.065h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.261 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M14.219 119.435q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.245 -.571 -.245 -1.333q.0 -.75 .245 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .566 .256 1.328zM10.355 119.435q.0 .922 .387 1.458q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" id="mol1atm9" stroke="none"/>
                  
            <g class="atom" id="mol1atm12">
                        
                <path d="M24.847 158.33q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 .0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM20.983 158.33q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M29.153 160.783h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M53.491 40.588h-.721l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M45.475 5.951q-.0 .649 -.477 1.018q-.47 .363 -1.268 .363q-.416 .0 -.767 -.065q-.346 -.06 -.578 -.173v-.589q.244 .113 .607 .202q.369 .089 .762 .089q.548 .0 .828 -.214q.28 -.214 .28 -.577q-.0 -.239 -.108 -.399q-.101 -.167 -.351 -.31q-.25 -.143 -.696 -.298q-.625 -.226 -.947 -.553q-.315 -.334 -.315 -.899q-.0 -.393 .196 -.667q.202 -.28 .554 -.429q.357 -.154 .815 -.154q.405 -.0 .738 .077q.34 .072 .614 .197l-.197 .529q-.25 -.113 -.548 -.184q-.297 -.078 -.625 -.078q-.458 .0 -.69 .197q-.232 .196 -.232 .518q-.0 .244 .101 .411q.107 .166 .339 .297q.232 .125 .631 .28q.429 .155 .727 .339q.297 .179 .452 .435q.155 .25 .155 .637z" fill="#C6C62C" id="mol1atm21" stroke="none"/>
                
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="26.386" x2="20.4525" y1="52.138" y2="52.5945"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="32.189" x2="35.2585" y1="55.487" y2="59.973"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="19.864" x2="25.797" y1="79.119" y2="78.6625"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="14.06" x2="10.9905" y1="75.77" y2="71.28399999999999"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="14.747" x2="12.343" y1="83.088" y2="88.1035"/>
            <line class="hi" id="mol1bnd9" stroke="#FF0D0D" x1="13.667" x2="16.107" y1="115.876" y2="110.7855"/>
            <line class="hi" id="mol1bnd10" stroke="#FF0D0D" x1="14.181" x2="17.374" y1="122.683" y2="127.3485"/>
            <line class="hi" id="mol1bnd12" stroke="#FF0D0D" x1="20.362" x2="17.171" y1="155.081" y2="150.41899999999998"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="31.502" x2="33.906" y1="48.169" y2="43.153999999999996"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="54.368" x2="57.734" y1="34.632" y2="30.441499999999998"/>
            <line class="hi" id="mol1bnd22" stroke="#C6C62C" x1="46.736" x2="52.191" y1="6.165" y2="8.7915"/>
            <line class="hi" id="mol1bnd23" stroke="#C6C62C" x1="41.14" x2="35.677" y1="6.157" y2="8.7875"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Antipsychotic Agents","Title":"Quetiapine","UNII":"BGL0JSY5SI","Wikidata":"Q408535","XLogP":2.1}